日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells.

结合多重 CRISPR/Cas9-切口酶和 PARP 抑制剂，可高效、精准地靶向癌细胞

期刊:Cancer Research
影响因子:16.6
doi:10.1158/0008-5472.CAN-24-2938
Lee Soyoung, Kim Kyunghwan, Jeong Hye-Jin, Choi Subin, Cheng Himchan, Kim Dayoung, Heo Soomin, Mun Jinhee, Kim Minjong, Lee Eunjin, Choi Yoon Ji, Lee Seon-Gyeong, Lee Eun A, Jang Yewon, Lim Kayeong, Kim Heon Seok, Jeong Euihwan, Myung Seung-Jae, Jung Deok-Beom, Yu Chang Sik, Song In Ho, Corces M Ryan, Kang Joo H, Myung Kyungjae, Kwon Taejoon, Park Tae-Eun, Joo Jinmyoung, Cho Seung Woo
细胞生物学
肿瘤免疫
发表日期：2025
文献求助 收藏

Bioprinted Patient-Derived Organoid Arrays Capture Intrinsic and Extrinsic Tumor Features for Advanced Personalized Medicine.

生物打印患者来源的类器官阵列捕获肿瘤的内在和外在特征，用于先进的个性化医疗

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202407871
Han Jonghyeuk, Jeong Hye-Jin, Choi Jeonghan, Kim Hyeonseo, Kwon Taejoon, Myung Kyungjae, Park Kyemyung, Park Jung In, Sánchez Samuel, Jung Deok-Beom, Yu Chang Sik, Song In Ho, Shim Jin-Hyung, Myung Seung-Jae, Kang Hyun-Wook, Park Tae-Eun
肿瘤
3D/类器官
发表日期：2025
文献求助 收藏

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

乌帕替尼治疗活动性非放射性中轴型脊柱关节炎：来自 SELECT-AXIS 2 3 期研究的 2 年数据

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-024-03441-3
Van den Bosch, Filip; Deodhar, Atul; Poddubnyy, Denis; Maksymowych, Walter P; van der Heijde, Désirée; Kim, Tae-Hwan; Kishimoto, Mitsumasa; Baraliakos, Xenofon; Bu, Xianwei; Lagunes-Galindo, Ivan; Song, In-Ho; Wung, Peter; Kato, Koji; Shmagel, Anna
关节炎
SELE
发表日期：2025
文献求助 收藏

Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis

针对中轴型脊柱关节炎患者，对乌帕替尼进行群体药代动力学和暴露-反应分析，以评估其疗效和安全性

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13733
Bhatnagar, Sumit; Eckert, Doerthe; Stodtmann, Sven; Song, In-Ho; Wung, Peter; Liu, Wei; Mohamed, Mohamed-Eslam F
关节炎
发表日期：2024
文献求助 收藏

Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial

乌帕替尼治疗活动性非放射性中轴型脊柱关节炎：一项双盲、随机、安慰剂对照的3期试验的1年数据

期刊:ACR Open Rheumatology
影响因子:2.8
doi:10.1002/acr2.11669
Van den Bosch, Filip; Deodhar, Atul; Poddubnyy, Denis; Maksymowych, Walter P; van der Heijde, Désirée; Kim, Tae-Hwan; Kishimoto, Mitsumasa; Baraliakos, Xenofon; Li, Yihan; D'Silva, Kristin; Wung, Peter; Song, In-Ho
关节炎
发表日期：2024
文献求助 收藏

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study

乌帕替尼治疗对生物制剂治疗无效的强直性脊柱炎患者的疗效和安全性：一项 III 期研究开放标签扩展研究的 1 年结果

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-023-03128-1
Baraliakos, Xenofon; van der Heijde, Désirée; Sieper, Joachim; Inman, Robert D; Kameda, Hideto; Li, Yihan; Bu, Xianwei; Shmagel, Anna; Wung, Peter; Song, In-Ho; Deodhar, Atul
强直性脊柱炎
免疫/内分泌
发表日期：2023
文献求助 收藏

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies

乌帕替尼治疗活动性银屑病关节炎伴中轴受累患者的疗效和安全性：两项3期研究的结果

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-023-03027-5
Baraliakos, Xenofon; Ranza, Roberto; Östör, Andrew; Ciccia, Francesco; Coates, Laura C; Rednic, Simona; Walsh, Jessica A; Douglas, Kevin; Gao, Tianming; Kato, Koji; Song, In-Ho; Ganz, Fabiana; Deodhar, Atul
关节炎
银屑病
发表日期：2023
文献求助 收藏

Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis

乌帕替尼对生物制剂难治性强直性脊柱炎患者的疾病活动度、疼痛、疲劳、功能、健康相关生活质量和工作效率的影响

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-023-00536-2
Navarro-Compán, Victoria; Baraliakos, Xenofon; Magrey, Marina; Östör, Andrew; Saffore, Christopher D; Mittal, Manish; Song, In-Ho; Ganz, Fabiana; Stigler, Jayne; Deodhar, Atul
强直性脊柱炎
免疫/内分泌
发表日期：2023
文献求助 收藏

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

乌帕替尼治疗生物制剂难治性活动性强直性脊柱炎的疗效和安全性：一项双盲、随机、安慰剂对照的3期试验

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard-2022-222608
van der Heijde, Désirée; Baraliakos, Xenofon; Sieper, Joachim; Deodhar, Atul; Inman, Robert D; Kameda, Hideto; Zeng, Xiaofeng; Sui, Yunxia; Bu, Xianwei; Pangan, Aileen L; Wung, Peter; Song, In-Ho
强直性脊柱炎
免疫/内分泌
发表日期：2022
文献求助 收藏

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension

乌帕替尼治疗对非甾体抗炎药治疗反应不足的活动性强直性脊柱炎患者的安全性和有效性：一项双盲、安慰剂对照研究和开放标签扩展研究的一年结果

期刊:Arthritis & Rheumatology
影响因子:10.9
doi:10.1002/art.41911
Deodhar, Atul; van der Heijde, Désirée; Sieper, Joachim; Van den Bosch, Filip; Maksymowych, Walter P; Kim, Tae-Hwan; Kishimoto, Mitsumasa; Ostor, Andrew; Combe, Bernard; Sui, Yunxia; Chu, Alvina D; Song, In-Ho
强直性脊柱炎
免疫/内分泌
发表日期：2022
文献求助 收藏